Thibaut F, Colonna L
SHU, C.H.S. du Rouvray, Sotteville-les-Rouen.
Encephale. 1992 Mar-Apr;18(2):193-8.
The use of lithium as an antiaggressive agent independently of its action in bipolar illness is now well documented. It appears particularly effective in the control of aggressive behavior in chronically aggressive prisoners and mentally retarded patients. Approximately 70-75% of these patients are likely to show a positive response to lithium therapy. No convincing features have been identified as being predictive of a good response. The clinical effect of lithium is to reduce the frequency and the severity of both hetero and auto aggressive outbursts. The use of lithium for aggressive behavior remains controversial in epileptic disorders and inconclusive in chronically psychotic patients. Careful monitoring of lithium blood levels is necessary to ensure adequate therapeutic efficacy without toxicity. A caution is needed in patients with brain damage especially when concurrent neuroleptic treatment is used. The antiaggressive effect of lithium seems rather specific and may be associated with a serotoninergic effect.
锂作为一种抗攻击剂使用，独立于其在双相情感障碍中的作用，目前已有充分的文献记载。它在控制慢性攻击性囚犯和智力迟钝患者的攻击行为方面似乎特别有效。这些患者中约70-75%可能对锂治疗有阳性反应。尚未确定有令人信服的特征可预测良好反应。锂的临床作用是减少异向和自向攻击发作的频率和严重程度。锂用于攻击行为在癫痫疾病中仍存在争议，在慢性精神病患者中尚无定论。仔细监测锂血药浓度对于确保充分的治疗效果而无毒性是必要的。脑损伤患者需要谨慎，尤其是在同时使用抗精神病药物治疗时。锂的抗攻击作用似乎相当特异，可能与5-羟色胺能效应有关。
